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Immune checkpoint inhibition has been shown to successfully reactivate endogenous 
T  cell responses directed against tumor-associated antigens, resulting in significantly 
prolonged overall survival in patients with various tumor entities. For malignancies with 
low endogenous immune responses, this approach has not shown a clear clinical benefit 
so far. Therapeutic vaccination, particularly dendritic cell (DC) vaccination, is a strategy to 
induce T cell responses. Interaction of DCs and T cells is dependent on receptor–ligand 
interactions of various immune checkpoints. In this study, we analyzed the influence of 
blocking antibodies targeting programmed cell death protein 1 (PD-1), HVEM, CD244, 
TIM-3, and lymphocyte activation gene 3 (LAG-3) on the proliferation and cytokine 
secretion of T  cells after stimulation with autologous TLR-matured DCs. In this con-
text, we found that LAG-3 blockade resulted in superior T cell activation compared to 
inhibition of other pathways, including PD-1/PD-L1. This result was consistent across 
different methods to measure T cell stimulation (proliferation, IFN-γ secretion), various 
stimulatory antigens (viral and bacterial peptide pool, specific viral antigen, specific tumor 
antigen), and seen for both CD4+ and CD8+ T cells. Only under conditions with a weak 
antigenic stimulus, particularly when combining antigen presentation by peripheral blood 
mononuclear cells with low concentrations of peptides, we observed the highest T cell 
stimulation with dual blockade of LAG-3 and PD-1 blockade. We conclude that priming 
of novel immune responses can be strongly enhanced by blockade of LAG-3 or dual 
blockade of LAG-3 and PD-1, depending on the strength of the antigenic stimulus.
Keywords: cancer immunotherapy, dendritic cell, immune checkpoint molecules, lag-3, PD-1, T cell response
Abbreviations: AML, acute myeloid leukemia; APC, antigen-presenting cell; CBA, cytometric bead array; CEFT, CMV, EBV, 
influenza, tetanus; CFSE, carboxyfluorescein N-succinimidyl ester; DC, dendritic cell; FLR, Epstein–Barr nuclear Ag 3  A 
peptide FLRGRAYGL; HD, healthy donor; LAG-3, lymphocyte activation gene 3; MACS, magnetic activated cell sorting; MFI, 
median fluorescence intensity; MHC, major histocompatibility complex; NAC, non-adherent cell; PB, peripheral blood; PBMC, 
peripheral blood mononuclear cell; PD-1, programmed cell death protein 1; PRAME, preferentially expressed antigen in 
melanoma; ORR, objective response rate; TCM, central memory T cell; TEM, effector memory T cell; TEMRA, effector memory RA 
T cell; Tnaive, naive T cell; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; TLR, toll-like receptor; TLR-3-DCs, 
dendritic cells generated within 3 days based on a TLR7/8 ligand; VLD, WT1 peptide VLDFAPPGA; WT1, Wilms Tumor 1.
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inTrODUcTiOn
Immunotherapy has changed our approach to anti-cancer treat-
ment in recent years. Checkpoint inhibitors have particularly been 
in the focus of clinical development and have shown remarkable 
success as monotherapy or as combination partners for various 
tumor entities. This has resulted in approval for different solid 
tumor entities, but also for Hodgkin lymphoma (1–4). Checkpoint 
blockade is thought to reactivate endogenous T  cell responses 
directed against tumor neoantigens presented in the context of 
major histocompatibility complex (MHC) molecules. In tumors 
with low endogenous T cell responses, however, the primary goal 
of immunotherapy needs to be the initiation of T cell responses 
directed against tumor-associated antigens. Various vaccination 
concepts are being pursued, and only recently, personalized 
neoantigen-based vaccines were shown to efficiently trigger T cell 
responses and lead to improved clinical outcome in patients with 
malignant melanoma (5, 6).
Dendritic cells (DCs) are particularly eligible to induce strong 
and durable immune responses. Over the years, multiple differ-
ent maturation protocols have been used to generate DCs from 
monocytes ex vivo (7), and the resulting DCs differ considerably 
in their immunostimulatory capacities. We have developed a 
GMP-compliant 3-day protocol for the generation of DCs with 
improved immunogenicity based on a toll-like receptor (TLR) 
7/8 ligand (TLR-3-DCs) (8). These DCs express higher numbers 
of co-stimulatory molecules and secrete higher levels of IL-12p70 
compared to DCs generated with the standard protocol (9). 
Currently, we are conducting a phase I/II study on vaccination 
with DCs loaded with Wilms Tumor 1 (WT1) and preferentially 
expressed antigen in melanoma as leukemia-associated antigens 
for postremission therapy of acute myeloid leukemia (AML) 
patients (10).
In order to further enhance immunological and clinical 
responses, multiple combinatorial approaches with DC vaccina-
tion can be considered. These include, but are not restricted to 
chemotherapy and radiotherapy, cytokines and TLR agonists, 
hypomethylating agents, but also more targeted strategies, such 
as elimination of immunosuppressive cell types (e.g., myeloid-
derived suppressor cells, regulatory T cells), molecularly targeted 
therapies and adoptive cell therapy (11, 12).
Another promising approach is the combination of DC vac-
cination with immune checkpoint inhibitors (13). Activated or 
chronically stimulated T  cells upregulate various co-inhibitory 
molecules, such as programmed cell death protein 1 (PD-1), 
CD244 (2B4), CD160, T-cell immunoglobulin and mucin-domain 
containing-3 (TIM-3, CD366), and lymphocyte activation gene 3 
(LAG-3, CD223) (14, 15). Their ligands are expressed both on 
antigen-presenting cells (APCs) and tumor cells. The inhibition 
of these checkpoints by blocking antibodies can, thus, enhance a 
vaccination-induced anti-cancer immune response in two ways. 
On the one hand, checkpoint inhibitors influence the interaction 
between T  cells and cancer cells, resulting in enhanced anti-
cancer T cell responses. On the other hand, checkpoint blockade 
may enhance the antigen-specific activation of T cells by DCs or 
other APCs. Studies performed in this field so far mainly focus on 
the inhibition of the PD-1/PD-L1 pathway (16–21).
Other co-inhibitory molecules, however, are also expressed on 
APCs, even on DCs after maturation with a TLR ligand (9). We, 
therefore, analyzed the effects of blocking various immune check-
points on the stimulation of T cells by autologous TLR-3-DCs, 
mainly using virus antigens as a model system. Besides PD-1, we 
tested HVEM, CD244, TIM-3, and particularly LAG-3.
LAG-3 is a member of the Ig superfamily that was identified in 
1990 (22). It is structurally similar to CD4 and binds MHC class 
II with a higher affinity than CD4 (23, 24). LAG-3 is expressed 
on activated CD4+ and CD8+ T  cells as well as on a subset of 
natural killer cells (22). By using a knock-out mouse model, 
LAG-3 was found to impede T cell expansion and to control the 
number of memory T  cells (25). Besides effector cells, LAG-3 
can also be found on the surface of T regulatory cells and seems 
to be instrumental for their suppressive activity (26) as well as 
for T cell homeostasis (27). Finally, LAG-3 is also expressed on 
plasmacytoid DCs (28). Thus, modulation of the LAG-3 pathway 
has the potential to impact autoimmunity and infections as well 
as cancer (29, 30). In three distinct transplantable tumor models, 
LAG-3 and PD-1 have been shown to be co-expressed on tumor-
infiltrating lymphocytes, and blockade of both pathways had 
synergistic effects on the anti-tumor CD8+ T cell response (31). 
Similarly in ovarian cancer patients, co-expression of LAG-3 and 
PD-1 was found on antigen-specific CD8+ T cells, and co-blockade 
of both lead to improved proliferation and cytokine production 
(32). Accordingly, different LAG-3 antibodies as monotherapy 
or in combination with anti-PD-1 have entered clinical trials for 
various cancer entities focusing on solid tumors.
In our model, we found that priming of T  cells by DCs is 
significantly enhanced by blockade of LAG-3. We, therefore, 
propose the combination of DC vaccination and LAG-3 block-
ade as a promising approach for the initiation of novel immune 
responses, particularly in tumors with low endogenous immune 
responses including AML.
MaTerials anD MeThODs
Media and reagents
Very low endotoxin RPMI 1640 medium (FG 1415; Biochrom) 
supplemented with 1.5% human serum (serum pool of AB posi-
tive adult males; Institute for Transfusion Medicine)—hereafter 
named DC medium—was used for the generation of DCs and all 
coculture experiments. The following reagents were used to gen-
erate DCs: GM-CSF (300-03), rhIL-4 (200-04), IFN-γ (300-02; all 
PeproTech), rhIL-1β (201-LB), TNF-α (210-TA/CF; both R&D 
Systems), PGE2 (P5640; Sigma-Aldrich), and R848 (tlrl-r848; 
InvivoGen).
cell isolation and generation of Dcs
After written informed consent, peripheral blood (PB) samples 
were collected from healthy donors (HDs) under a clinical proto-
col entitled “in vitro studies to establish new immunotherapies for 
AML and other hematological neoplasias.” Both the consent form 
and the protocol were approved by the institutional review board 
(Ethikkommission bei der LMU München). Both cell isolation 
and generation of DCs were performed as described previously 
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for TLR-3-DCs (9) with the exception of polyI:C, which was not 
included in the maturation cocktail.
coculture of Dcs and T cells
Dendritic cells were pulsed with a mixed CMV, EBV, influenza, 
and tetanus (CEFT) peptide pool (2 µg/ml; PM-CEFT; JPT) for 
2 h at 37°C, 5% CO2, incubated for 10 min on ice and subse-
quently washed. CD3+ T  cells were isolated from autologous 
non-adherent cells (NACs) by magnetic activated cell sorting 
(MACS, 130-050-101; Miltenyi Biotec) according to the manu-
facturer’s protocol. CEFT-pulsed DCs and CD3+ T  cells were 
cocultured at a ratio of 1:10 in 96-well round bottom plates 
for 4 days at 37°C, 5% CO2. For blocking experiments, the fol-
lowing monoclonal blocking antibodies were added at 10  µg/
ml: α-CD244 (PP35; 16-2449-81; eBioscience), α-HVEM (122; 
318802), α-TIM-3 (F38-2E2; 345003), α-PD-1 (EH12.27H7; 
329911; all BioLegend), α-LAG-3 (17B4; AG-20B-0012PF; 
AdipoGen or ab40466; Abcam). The blocking antibody concen-
tration of 10 µg/ml that we used was based on prior experiments 
demonstrating antibody blockade of immune checkpoints (21). 
Reducing the antibody concentration to 5 µg/ml did not alter our 
results (data not shown).
coculture of Dcs and nacs
Dendritic cells were pulsed with the Epstein–Barr nuclear Ag 3 A 
peptide FLRGRAYGL (FLR) (2 µg/ml; JPT) for 2 h at 37°C, 5% 
CO2 and subsequently washed. FLR-pulsed DCs and autologous 
NACs were cocultured at a ratio of 1:80 in 96-well round bottom 
plates for 6 days at 37°C, 5% CO2. For blocking experiments, α-
PD-1 and α-LAG-3 were added as above.
culture of PBMcs
Peripheral blood mononuclear cells (PBMCs) were loaded with 
FLR and cultured in 96-well round bottom plates (5 × 105/well) 
in the presence or absence of α-PD-1 and α-LAG-3 for 6–8 days 
at 37°C, 5% CO2.
surface Phenotyping of Dcs and T cells
Immunofluorescent staining of DC surface antigens was performed 
using a panel of fluorescence-conjugated monoclonal antibodies: 
CD80 (PE, L307.4; 560925), CD83 (APC, HB15e; 551073) CD86 
(FITC, 2331 (FUN-1); 557343), CD273 (APC, MIH18; 557926), 
CD274 (FITC, MIH1; 558065; all BD Biosciences), Galectin-9 (PE, 
9M1-3; 348906), CD48 (FITC, BJ40; 336706), HLA-DR (Pacific 
Blue, LN3; 327016; all BioLegend), HVEM (APC, 94801; FAB356A; 
R&D Systems). Corresponding isotype controls were used.
Immunofluorescent staining of T-cell surface antigens was per-
formed using the following fluorescence-conjugated monoclonal 
antibodies: CD244 (PE, C1.7; 329507 or APC, C1.7; 329511), 
PD-1 (Brilliant Violet 421, EH12.7H7; 329919), CD3 (FITC, 
UCHT1; 300406), CD45RA (Brilliant Violet 421, HI100; 304129; 
all BioLegend), CD160 (APC, 688327; FAB6700A), TIM-3 (PE, 
344823; FAB2365P; both R&D Systems), CD8 (PerCP-eFluor 710, 
SK1; 8046-0087; eBioscience), CD4 (APC-H7, RPA-T4; 560158; 
BD Biosciences), LAG-3 (ATTO 647N, 17B4; AG-20B-0012TS 
AdipoGen), CCR7 (CD197, APC, FR 11-11E8; 130-098-125; 
Miltenyi Biotec). Corresponding isotype controls were used. 
Intracellular FoxP3 staining was performed according to the 
manufacturer’s instructions (APC, 3G3; Miltenyi Biotec).
Cells were analyzed using a FACS LSR II (BD Biosciences). 
Post-acquisition analysis was performed using FlowJo software 
(version 9.7.6; Tree Star). The median fluorescence intensity 
(MFI) ratio was calculated by dividing the MFI of the measured 
population by the MFI of cells stained with the isotype-matched 
antibody. For the upregulation of checkpoint molecules, the 
percentage of positive cells (% positive) was obtained by setting 
the gate at or below 1% in the respective isotype control.
cytokine secretion Measurement by 
Bead-Based immunoassay
Secretion of IFN-γ and TNF-α was quantified by cytometric bead 
array (CBA) Flex Set (560111; BD Biosciences) according to the 
manufacturer’s instructions.
cFse Proliferation assay
Isolated CD3+ T  cells were labeled with carboxyfluorescein 
N-succinimidyl ester (CFSE, C34554; Life Technologies) and 
cultured in the presence of autologous DCs. Unstimulated T cells 
served as negative control. Harvested cells were then stained 
with antibodies for CD3 (APC, UCHT1; 300412; BioLegend), 
CD4 (APC-H7), and CD8 (PerCP-eFluor 710). The percentage 
of divided cells (% divided) was analyzed using FlowJo software.
Fluorescence-Based cell sorting
Magnetic activated cell sorting-enriched CD3+ T cells were sorted 
according to CCR7 and CD45RA expression levels into naive 
T  cells (Tnaive), central memory T  cells (TCM), effector memory 
T cells (TEM), and effector memory RA T cells (TEMRA) using an 
Aria III (BD Biosciences).
expansion of WT1 Peptide-specific T cells
Wilms Tumor 1 antigen VLD (VLD  =  WT1 peptide 
VLDFAPPGA)-specific T  cells were generated as previously 
described (33). Briefly, DCs were matured as described above. 
Autologous CD8+ T  cells were isolated from NACs using the 
CD8+ T Cell Isolation Kit (130-096-495; Miltenyi Biotec) and 
incubated overnight in VLE-RPMI medium supplemented with 
5% human serum and 5 ng/ml of IL-7 (200-07; Peprotech). DCs 
were pulsed with 2.5 µL/ml of the HLA-A*02:01-restricted VLD 
peptide (VLDFAPPGA; JPT) for 90  min and irradiated with 
30 Gy. CD8+ T cells and DCs were cocultivated in a 4:1 T cell:DC 
ratio and incubated with 30 ng/ml of IL-21 (200-21; Peprotech) 
in the presence or absence of 10 µg/ml LAG-3 or PD-1 block-
ing antibodies for 72  h. On day 3, cocultures were expanded 
1:1 by adding medium supplemented with 10 ng/ml IL-15 and 
IL-7 (200-07, 200-15; both Peprotech) and 10  µg/ml blocking 
antibodies. On days 6–7, cells were analyzed by flow cytometry 
using VLD multimer (WB3469; Immudex) and fluorescence-
conjugated monoclonal antibodies (see above).
statistical analysis
Data were analyzed using Prism 6 (GraphPad Software). All 
results are presented in box-and-whisker plots, with boxes 
FigUre 2 | Upregulation of immune checkpoint ligands on T cells after 
dendritic cell stimulation. T cells of 7–14 healthy donor were cocultured with 
autologous TLR-3-DCs pulsed with CMV, EBV, influenza, tetanus (CEFT) 
peptide pool or with CEFT peptide pool alone. Expression of various 
inhibitory checkpoint molecules was analyzed by flow cytometry. The 
percentage of positive cells is presented as box-and-whisker plots for CD4+ 
(a) and for CD8+ (B) T cells. *p < 0.05; **p < 0.01.
FigUre 1 | Immunophenotypic characterization of dendritic cells generated 
within 3 days based on a TLR7/8 ligand (TLR-3-DCs). TLR-3-DCs were 
generated from peripheral blood of healthy donor (HDs), and surface marker 
expression was measured by flow cytometry. (a) The characteristic 
phenotype of a dendritic cell population (FSChi/SSChi/CD14-/CD83+/
CD80+/CD86+) is shown for one representative donor. (B) Expression of 
various inhibitory checkpoint molecules was analyzed on TLR-3-DCs of 3–10 
donors, and MFI ratio of the expression is presented as box-and-whisker 
plots.
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representing the lower quartile, the median and the upper 
quartile, while the whiskers show the minimal and the maximal 
value. The significance of differences for pairwise comparison 
was determined using the two-tailed Wilcoxon signed rank test. 
p < 0.05 was considered statistically significant (* in all figures), 
while p < 0.01 is termed highly significant (** in all figures).
resUlTs
Tlr-3-Dcs expressed PD-l1 and hla-Dr
TLR-3-DCs were generated from PB of HDs. The characteristic 
phenotype of these DCs, with high expression of CD83, CD86, 
and CD80 and downregulation of CD14 is shown in Figure 1A. 
Expression of various inhibitory checkpoint molecules on DCs 
was analyzed by flow cytometry on 3–10 of these samples. 
HLA-DR was added to the panel as ligand for lymphocyte activa-
tion gene 3 (LAG-3) on T cells. MFI ratio of the expression data is 
presented in Figure 1B, statistical significance was tested against 
a theoretical median of 1.5. The expression of PD-L1 (median 6.2; 
n = 7; p = 0.004) and HLA-DR (median 184.5; n = 7; p = 0.016) 
on TLR-3-DCs was found to be (highly) significant. By contrast, 
HVEM (median 2.0; n = 10), CD48 (median 2.5; n = 7), Gal-9 
(median 0.8; n =  7), and PD-L2 (median 0.9; n =  3) were not 
significantly expressed (Figure 1B).
cD244, TiM-3, PD-1, and lag-3 Were 
Upregulated on T cells after stimulation 
with Tlr-3-Dcs
Expression of the respective co-inhibitory ligands was determined 
on T cells with and without stimulation by DCs. TLR-3-DCs were 
generated from PB of HDs and pulsed with CEFT peptide pool. 
CD3+ T cells were isolated from PB of the same HDs and cocul-
tured with autologous DCs or with CEFT peptide pool alone for 
96 h. Expression of various inhibitory checkpoint molecules was 
analyzed on T cells by flow cytometry for 7–14 HDs. The percent-
age of positive cells is presented for CD4+ (Figure 2A; Figure S1 
in Supplementary Material) and CD8+ (Figure  2B; Figure S1 
in Supplementary Material) T  cells. Statistical significance was 
tested between stimulation with pulsed DCs and CEFT stimula-
tion alone as a control. CD4+ T cells showed a (highly) significant 
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upregulation of CD244 (median of 2.3 vs. 1.5%; n = 7; p = 0.047), 
TIM-3 (median of 24.3 vs. 4.2%; n =  7; p =  0.016) and PD-1 
(median of 16.4 vs. 5.9%; n =  13; p =  0.003) after stimulation 
with TLR-DCs, while expression of CD160 (median of 3.3 vs. 
5.9%; n = 7) and LAG-3 (median of 1.8 vs. 0.7%; n = 9) were not 
changed (Figure 2A). On CD8+ T cells, we found (highly) sig-
nificant upregulation of CD244 (median of 30.2 vs. 13.9%; n = 8; 
p = 0.008), TIM-3 (median of 30.8 vs. 3.9%; n = 8; p = 0.008), 
PD-1 (median of 21.5 vs. 13.4%; n = 14; p < 0.001) and LAG-3 
(median of 5.4 vs. 0.4%; n =  9; p =  0.027), but not of CD160 
(median of 4.5% vs. 5.0%; n = 8) (Figure 2B).
Blockade of PD-1 and lag-3, but not 
hVeM, cD244 or TiM-3, enhanced 
Proliferation of T cells after stimulation 
with Tlr-3-Dcs
In order to determine the functional relevance of co-inhibitory 
molecule interaction between TLR-3-DCs and T  cells, we first 
tested the influence of checkpoint blockade on proliferation of 
T cells after DC stimulation. CD3+ T cells isolated from PB of 
HDs were labeled with CFSE and cocultured with autologous 
CEFT-pulsed TLR-3-DCs for 5 days in the presence or absence 
of respective blocking antibodies. The percentage of divided 
cells was determined by flow cytometry. The ratio between the 
percentages of divided cells with and without blocking antibody 
was calculated. Data for 4–13 samples is presented in Figure 3A 
for CD4+ T  cells and in Figure  3B for CD8+ T  cells, original 
data is shown in Table S1 in Supplementary Material. Statistical 
significance was calculated against a fold change of 1.0, equal to 
no effect of the blocking antibody on proliferation. For CD4+ 
T  cells, no effect of checkpoint blockade on proliferation was 
found for HVEM (fold change 0.91; n = 6), CD244 (fold change 
1.05; n = 4) and TIM-3 (fold change 1.02; n = 4). Blockade of 
PD-1 resulted in slightly enhanced proliferation (fold change 
1.15; n = 13; p = 0.002), and blockade of LAG-3 lead to markedly 
enhanced proliferation (fold change 1.44; n = 9; p = 0.002), both 
statistically highly significant (Figure  3A). Similarly, for CD8+ 
T cells, blockade of PD-1 resulted in slightly enhanced prolifera-
tion (fold change 1.08; n = 13; p = 0.003), and blockade of LAG-3 
lead to markedly enhanced proliferation (fold change 1.24; n = 9; 
p = 0.002), both statistically highly significant, while no effect of 
checkpoint blockade on proliferation was found for HVEM (fold 
change 0.88; n = 6), CD244 (fold change 0.96; n = 4) and TIM-3 
(fold change 0.91; n = 4) (Figure 3B).
Blockade of PD-1 and lag-3, but not 
hVeM, cD244 or TiM-3, enhanced iFn-γ 
and TnF-α secretion by T cells after 
stimulation with Tlr-3-Dcs
Next, we determined whether checkpoint blockade also influ-
enced IFN-γ and TNF-α secretion by T cells after DC stimula-
tion. CD3+ T cells isolated from PB of HDs were cocultured with 
autologous CEFT-pulsed TLR-3-DCs for 96 h in the presence or 
absence of respective blocking antibodies. The concentration of 
IFN-γ and TNF-α in the culture supernatant was determined by 
CBA. IFN-γ and TNF-α fold change was calculated by dividing 
the concentration of the coculture with blocking antibody by the 
concentration of the control coculture without antibody. Data 
for 5–14 samples is presented for IFN-γ in Figure 3C, statistical 
significance was calculated against a fold change of 1.0, original 
data are shown in Table S1 in Supplementary Material. No effect 
of checkpoint blockade on IFN-γ secretion was found for HVEM 
(fold change 0.63; n = 7), CD244 (fold change 0.86; n = 5), and 
TIM-3 (fold change 1.01; n = 5). Blockade of PD-1 resulted in 
enhanced IFN-γ secretion (fold change 1.50; n = 14; p = 0.002) 
and blockade of LAG-3 lead to markedly enhanced IFN-γ secre-
tion (fold change 5.00; n = 9; p = 0.004), both statistically highly 
significant (Figure 3C). Similarly, no effect of checkpoint block-
ade on TNF-α secretion was found for HVEM (fold change 0.89; 
n = 7), CD244 (fold change 1.01; n = 5) and TIM-3 (fold change 
0.92; n = 5), while blockade of PD-1 (fold change 1.69; n = 14; 
p =  0.002), and blockade of LAG-3 (fold change 5.29; n =  9; 
p = 0.008) resulted in enhanced TNF-α secretion, both statisti-
cally highly significant (Figure S2 in Supplementary Material).
combination with PD-1 Blockade resulted 
in an increase of iFn-γ secretion, but not 
in an enhanced Proliferation of T cells 
after stimulation with Tlr-3-Dcs 
compared to lag-3 Blockade alone
We tested the hypothesis that blockade of PD-1 and LAG-3 has 
additive or synergistic effects on proliferation or IFN-γ secretion 
by T  cells after stimulation with TLR-3-DCs. For proliferation 
assays, CD3+ T cells isolated from PB of 7 HDs were labeled with 
CFSE and cocultured with autologous TLR-3-DCs for 5  days 
in the presence or absence of blocking antibodies for PD-1 and 
LAG-3, both alone and in combination. As above, the percentage 
of divided cells was determined by flow cytometry for the differ-
ent conditions, and the ratio between the percentages of divided 
cells with and without blocking antibody was calculated. Data 
are presented in Figure 3D for CD4+ T cells and in Figure 3E 
for CD8+ T  cells, statistical significance was calculated for the 
combination of blocking antibodies vs. single antibody blockade, 
original data are shown in Table S1 in Supplementary Material. 
For the combination of PD-1 and LAG-3 blockade (median 
fold change of 1.37 for CD4+ and 1.26 for CD8+), we found sig-
nificantly higher T cell proliferation compared to PD-1 blockade 
alone (median fold change of 1.02 for CD4+; p = 0.016; 1.02 for 
CD8+; p =  0.016), but no difference to LAG-3 blockade alone 
(median fold change of 1.31 for CD4+; p = 0.094; 1.20 for CD8+; 
p = 0.250).
Similarly, for IFN-γ secretion assays, CD3+ T  cells isolated 
from PB of 8 HDs were cocultured with autologous CEFT-pulsed 
TLR-3-DCs for 96 h in the presence or absence of blocking anti-
bodies for PD-1 and LAG-3, both alone and in combination. The 
concentration of IFN-γ in the culture supernatant was determined 
by CBA. IFN-γ fold change was calculated as a ratio between the 
IFN-γ concentration of the coculture with and without blocking 
antibody. Statistical significance was calculated for the combina-
tion of blocking antibodies vs. single antibody blockade. For the 
combination of PD-1 and LAG-3 blockade (median fold change 
FigUre 3 | Effect of immune checkpoint blockade on proliferation and IFN-γ secretion of T cells after stimulation with TLR-3-DCs. CD3+ T cells of 4–14 healthy donor 
(HDs) were cocultured with autologous CMV, EBV, influenza, tetanus (CEFT)-pulsed TLR-3-DCs in the presence or absence of immune checkpoint blocking antibodies, 
either for individual antibodies (a–c) or in different combinations of α-PD-1 and α-LAG-3 antibodies (D–F). Proliferation of CD4+ (a,D) and CD8+ T cells (B,e) was 
analyzed by carboxyfluorescein N-succinimidyl ester (CFSE) assay, and the ratio between the percentages of divided cells with and without blocking antibody was 
calculated. IFN-γ secretion of CD3+ T cells (c,F) was determined by cytometric bead array (CBA) assay, and the ratio between concentration with and without blocking 
antibody was calculated. All data are presented as box-and-whisker plots, and statistical significance was calculated against a fold change of 1.0. *p < 0.05; **p < 0.01.
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FigUre 4 | Effect of programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) blockade on IFN-γ secretion of different T cell 
subpopulations after stimulation with TLR-3-DCs. MACS-enriched CD3+ T cells of 8 healthy donor (HDs) were sorted according to CCR7 and CD45 RA expression 
(a). The various T cell subpopulations were cocultured with autologous CMV, EBV, influenza, tetanus (CEFT)-pulsed TLR-3-DCs in the presence or absence of 
α-PD-1 (B) and α-LAG-3 (c) antibody. IFN-γ secretion was determined by cytometric bead array (CBA) assay, and the ratio between concentration with and without 
blocking antibody was calculated. All data are presented as box-and-whisker plots, and statistical significance was calculated against a fold change of 1.0. 
*p < 0.05.
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of 2.80), the increase in IFN-γ secretion compared to PD-1 block-
ade alone was statistically highly significant (median fold change 
of 1.41; p = 0.008). In comparison to LAG-3 blockade alone, we 
found a slight, but statistically significant enhancement (median 
fold change of 2.70; p  =  0.016) (Figure  3F). Taken together, 
LAG-3 blockade alone resulted in strong enhancement of T cell 
proliferation and IFN-γ secretion. The effect on IFN-γ secretion 
was slightly increased by the combination with PD-1 blockade, 
while no additional effect was seen for T cell proliferation.
lag-3 Blockade Mainly enhanced iFn-γ 
secretion by naive and TcM, While PD-1 
Blockade also resulted in an increase of 
iFn-γ secretion by effector Memory cells
Next, we analyzed the differential effect of PD-1 and LAG-3 
blockade on T  cell subpopulations. MACS-enriched CD3+ 
T  cells were sorted according to CCR7 and CD45RA expres-
sion levels into Tnaive, TCM, TEM, and TEMRA T cells (Figure 4A). 
The various T cell populations were cocultured with autologous 
CEFT-pulsed TLR-3-DCs for 96  h in the absence of presence 
of blocking antibodies for PD-1 and LAG-3. Again, the con-
centration of IFN-γ in the culture supernatant was determined 
by CBA. IFN-γ fold change was calculated by dividing the 
concentration of the coculture with blocking antibody by the 
concentration of the control coculture without antibody. Data 
for six samples is presented for PD-1 (Figure 4B) and for LAG-3 
(Figure  4C) blockade. Statistical significance was calculated 
against a fold change of 1.0. We found that PD-1 blockade lead 
to significantly increased IFN-γ secretion of Tnaive (median fold 
change of 1.41; p =  0.031), TCM (median fold change of 1.43; 
p =  0.031), and TEM (median fold change of 1.47; p =  0.031), 
while the increased secretion of TEMRA was not statistically 
significant (median fold change of 1.96; p = 0.156) (Figure 4B). 
By contrast, LAG-3 blockade had significant effects on IFN-γ 
secretion of Tnaive (median fold change of 2.04; p = 0.031) and TCM 
(median fold change of 1.71; p = 0.031), but not on TEM (median 
fold change of 1.34; p = 0.094) and TEMRA (median fold change 
of 1.33; p =  0.094) (Figure  4C). With respect to the CD25+/
FoxP3+ regulatory T cell subpopulation of CD4+ T cells, we saw 
a tendency toward a higher percentage after LAG-3 blockade 
(Figure S3 in Supplementary Material).
FigUre 5 | Effect of programmed cell death protein 1 (PD-1) and 
lymphocyte activation gene 3 (LAG-3) blockade on proliferation of EBV 
antigen-specific T cells after stimulation with TLR-3-DCs. non-adherent cell 
(NACs) of 9 healthy donor (HDs) were cocultured with autologous 
Epstein–Barr nuclear Ag 3 A peptide FLRGRAYGL (FLR)-pulsed TLR-3-DCs 
in the presence or absence of α-PD-1 and α-LAG-3 antibody. (a) The 
percentage of FLR tetramer positive cells within the CD8+ T cell population 
was determined by flow cytometry. Data for fold change to the condition 
without blocking antibody are presented as box-and-whisker plots, and 
statistical significance was calculated against a fold change of 1.0. 
*p < 0.05. (B) PD-1 and LAG-3 expression was determined for FLR 
tetramer positive CD8+ T cells after stimulation with non-pulsed or 
FLR-pulsed TLR-3-DCs.
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Blockade of lag-3, but not PD-1, 
enhanced Proliferation of eBV antigen-
specific T cells after stimulation with 
Tlr-3-Dcs
Next, we tested whether blockade of PD-1 and LAG-3 also 
enhances the proliferation of antigen-specific T cells after stimu-
lation with TLR-3-DCs. NACs (mainly consisting of T cells) of 9 
HDs were cocultured with autologous FLR-pulsed TLR-3-DCs 
for 144 h in the presence or absence of blocking antibodies for 
PD-1 and LAG-3, both alone and in combination. The percent-
age of FLR tetramer positive (Tet+) cells within the CD8+ T cell 
population was determined by flow cytometry. Tet+ fold change 
was calculated by dividing the percentage in the condition with 
blocking antibody by the percentage in the condition without 
any antibody. Statistical significance was calculated against a 
fold change of 1.0. Blockade of LAG-3 resulted in a significantly 
increased percentage of Tet+ CD8+ T cells (median fold change 
1.69; p =  0.039), while blockade of PD-1 (median fold change 
0.79) and the combination of LAG-3 and PD-1 blockade (median 
fold change 0.61) did not enhance the percentage of antigen-
specific T cells (Figure 5A). This was not due to a lack of PD-1 
expression on T cells, as further analysis of the Tet+ CD8+ T cells 
after stimulation with FLR-pulsed DCs revealed that PD-1 was 
expressed on 92.6% of the T cells, while LAG-3 was found on only 
49.1% of T cells (Figure 5B).
Blockade of lag-3, but not PD-1, 
enhanced Proliferation and iFn-γ 
secretion of T cells after stimulation with 
Flr-Pulsed aPcs within PBMcs
We then asked if the effect of LAG-3 blockade on proliferation 
and IFN-γ secretion also holds true, if T cells are not stimulated 
by TLR-3-DCs, but by the various APCs naturally occurring 
within PBMCs. PBMCs of 8 HDs were pulsed with FLR peptide 
and cultured for 6 days in the presence or absence of blocking 
antibodies for PD-1 and LAG-3, both alone and in combina-
tion. Thereafter, the percentage of FLR tetramer positive cells 
(Tet+) within the CD8+ T  cell population was determined 
by flow cytometry. Tet+ fold change was calculated by divid-
ing the percentage in the condition with blocking antibody 
by the percentage in the condition without any antibody. 
Statistical significance was calculated against a fold change of 
1.0. Blockade of LAG-3 resulted in a significantly increased 
percentage of Tet+ CD8+ T  cells (median fold change 1.80; 
p = 0.023), while blockade of PD-1 (median fold change 1.05) 
did not enhance the percentage of antigen-specific T cells. The 
combination of LAG-3 and PD-1 blockade also significantly 
enhanced the percentage of Tet+ CD8+ T  cells (median fold 
change 1.74; p = 0.016), but this was not different from LAG-3 
alone (p = 0.461) (Figure 6A).
The concentration of IFN-γ was determined in the culture 
supernatant after 6–8  days of coculture by CBA. IFN-γ fold 
change was calculated by dividing the concentration of the cocul-
ture with blocking antibody by the concentration of the control 
coculture without antibody. Data for the same eight samples is 
presented in Figure  6B, statistical significance was calculated 
against a fold change of 1.0. Blockade of PD-1 (median fold 
change 0.96) did not enhance IFN-γ secretion, while increase 
of IFN-γ secretion after blockade of LAG-3 was highly signifi-
cant (median fold change 4.07; p = 0.008). The combination of 
LAG-3 and PD-1 blockade also enhanced IFN-γ secretion highly 
significantly (median fold change 6.88; p = 0.008), but the dif-
ference to LAG-3 blockade alone was not significant (p = 0.188) 
(Figure 6B).
Further analysis of the Tet+ CD8+ T cells after stimulation with 
FLR-pulsed PBMCs revealed that PD-1 was expressed on almost 
all of the T cells (93.3%), while LAG-3 was found on only 10.5% 
of T cells (Figure 6C). Therefore, the non-existent effect of PD-1 
blockade in this setting was not due to an absence of PD-1 on the 
T cell surface.
FigUre 6 | Effect of programmed cell death protein 1 (PD-1) and 
lymphocyte activation gene 3 (LAG-3) blockade on proliferation and IFN-γ 
secretion of EBV antigen-specific T cells after stimulation with antigen-
presenting cells (APC) within peripheral blood mononuclear cells (PBMCs). 
Epstein–Barr nuclear Ag 3 A peptide FLRGRAYGL (FLR) peptide-pulsed 
PBMCs of 8 healthy donor (HDs) were cultered in the presence or absence of 
α-PD-1 and α-LAG-3 antibody. The percentage of FLR tetramer positive cells 
within the CD8+ T cell population was determined by flow cytometry (a), and 
IFN-γ secretion was determined by cytometric bead array (CBA) assay (B). 
Data for fold change to the condition without blocking antibody are 
presented as box-and-whisker plots, and statistical significance was 
calculated against a fold change of 1.0. * p < 0.05; **p < 0.01. (c) PD-1 and 
LAG-3 expression was determined for FLR tetramer positive CD8+ T cells 
after stimulation with non-pulsed or FLR-pulsed PBMCs.
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Blockade of lag-3, More than PD-1, 
enhanced expansion of WT1 Tumor 
antigen-specific T cells after stimulation 
with Tlr-3-Dcs
Finally, we tested the hypothesis that the effect of LAG-3 
blockade on proliferation of antigen-specific T cells can also be 
transferred to tumor antigen specificity. CD8+ T cells of 3 HDs 
were cocultured with autologous TLR-3-DCs pulsed with a WT1 
antigen (VLD peptide) for 6–7 days in the presence or absence of 
blocking antibodies for PD-1 and LAG-3. The percentage of VLD 
tetramer positive (Tet+) cells within the CD8+ T cell population 
was determined by flow cytometry. Results for all three donors 
are presented in Figure  7. Blockade of LAG-3 resulted in an 
increased percentage of Tet+ CD8+ T cells in two of three cases, 
while blockade of PD-1 resulted in an increase in Tet+ CD8+ 
T cells in only one case, and to a lesser extent.
DiscUssiOn
Over the last decades, DCs generated in vitro for the vaccination 
of tumor patients have been optimized with respect to cytokine 
production as well as co-stimulatory molecule expression. 
However, even TLR-3-DCs, which demonstrate an improved 
phenotype and functional profile, express co-inhibitory molecules 
(9). Combining DC vaccination with checkpoint inhibition is, 
therefore, conceivable and might enhance T cell responses.
In this study, we systematically analyzed the effect of different 
checkpoint inhibitors on T cell stimulation by TLR-3-DCs. We 
found that within our experimental settings, blockade of LAG-3 
was consistently superior to PD-1 blockade, independently of 
the method to measure T cell stimulation (proliferation, IFN-γ 
secretion), the stimulating antigen (viral and bacterial peptide 
pool, specific viral antigen, specific tumor antigen), and the type 
of T cell (CD4+ and CD8+ T cells) used. This was not expected, 
as LAG-3 expression on T  cells is relatively low compared to 
PD-1 expression and only slightly upregulated after stimulation. 
However, it has to be considered that checkpoint molecules are 
often upregulated on antigen-specific T  cells only (Figure S4A 
in Supplementary Material) and, thus, the assessment of bulk 
T  cell populations might only insufficiently reflect checkpoint 
molecule expression. Besides, HLA-DR as the main ligand for 
LAG-3 is much higher expressed on APCs including TLR-3-DCs 
than any co-inhibitory molecules (Figure 1), conceivably result-
ing in numerous receptor–ligand interactions with T  cells that 
help to explain the strong effects seen in our blocking experi-
ments. LSECtin, a cell surface lectin of the DC-SIGN family, has 
been identified as an alternative ligand for LAG-3, and LAG-3 
blockade has been shown to result in abrogation of immunoin-
hibitory effects of LSECtin in a melanoma mouse model (34). As 
LSECtin is only marginally expressed on TLR-3-DCs (Figure S5 
in Supplementary Material), the effects of LAG-3 blockade dem-
onstrated here are more likely due to interaction with HLA-DR. 
Similarly, the low PD-L2 expression on DCs suggests that PD-L1 
is more relevant for the interaction with PD-1 in our setting. 
However, we cannot rule out that other receptor–ligand interac-
tions between DCs and T cells that have not yet been explored are 
responsible for the effects on T cell responses that we describe. In 
order to further elucidate the mechanism of action, a potential 
approach could be the application of MHC class II blocking 
antibodies. In a model using COS-7 cells transfected with human 
LAG-3 and MHC class II-expressing human B lymphoblastic cell 
lines, it could be shown that both blocking antibodies against 
LAG-3 and HLA-DR were able to disrupt the rosettes formed by 
these cells (23). However, the exact binding site on MHC class 
II for LAG-3 is still unknown making the choice of an antibody 
that specifically blocks the interaction of MHC II with LAG-3 
technically challenging.
In a recently published study that analyzed the effects of 
checkpoint blockade on T cell stimulation by allogeneic DCs, the 
addition of an antibody directed against LAG-3 to the coculture 
FigUre 7 | Effect of programmed cell death protein 1 (PD-1) and lymphocyte activation gene 3 (LAG-3) blockade on proliferation of Wilms Tumor 1 tumor-antigen-
specific T cells after stimulation with TLR-3-DCs. CD8+ T cells of three healthy donor (HDs) were cocultured with autologous VLD-pulsed. TLR-3-DCs in the 
presence or absence of α-PD-1 and α-LAG-3 antibody. The percentage of VLD tetramer positive cells within the CD8+ T cell population was determined by flow 
cytometry. Data for all three donors are shown.
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did not result in significant changes in T  cell proliferation or 
cytokine secretion (21). As the setting of these experiments dif-
fered from ours in the origin of the blood donors (allogeneic vs. 
autologous), maturation protocol of the DCs and target antigens, 
there are multiple reasons for the diverging results. However, it 
is also important to notice that the LAG-3 antibody used is of a 
different clone and its blockade of the ligand–receptor interac-
tions might be less effective than in our experiments. While we 
did not directly proof that the antibodies we used were blocking 
the interaction with their ligands, we only chose antibodies that 
had been described in the literature to have this capacity. Besides, 
we showed that addition of the blocking antibodies reduced the 
capacity of the respective staining antibody to bind to the recep-
tor (Figure S4B in Supplementary Material).
While the effects of PD-1 blockade on T  cell stimulation by 
TLR-3-DCs were less pronounced than those of LAG-3 blockade 
in our experiments, they were still significant. Surprisingly, how-
ever, the combination of both blocking antibodies did not result 
in a relevant increase in T cell stimulation compared to the LAG-3 
antibody alone. In the analysis of viral antigen-specific T  cell 
stimulation, it was even deleterious (Figure  5). Several murine 
tumor models, including a B16 melanoma and an MC38 colon 
adenocarcinoma model (31) demonstrated synergistic anti-tumor 
immunity by dual blockade of PD-1 and LAG-3. One possible 
explanation for our observation is an overstimulation of T cells 
by the combination of the immunostimulatory TLR-3-DCs with 
two effective checkpoint inhibitors. This is in line with data pub-
lished for chronic lymphocytic leukemia, where PD-1 blockade 
abolished the positive effect induced by anti-LAG-3 antibodies in 
combination with CD3/CD28 beads as a very strong stimulus (35).
This hypothesis was substantiated in our experiments 
using PBMCs, comprising APCs that are relatively less 
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immunostimulatory compared to TLR-3-DCs. Here, the combi-
nation of both blocking antibodies resulted in T cell stimulation 
that was at least similar to the LAG-3 antibody alone (Figure 6). 
As the strength of the antigen stimulus is also dependent on pep-
tide concentration, we conducted peptide titration assays in the 
setting of viral antigen-specific T cell stimulation both by TLR-
3-DCs and by PBMCs (Figure S6 in Supplementary Material). 
At the lowest peptide concentration, the combinatorial blockade 
was equally effective to LAG-3 blockade alone for DCs, while the 
effect of LAG-3 blockade on PBMCs was strongly increased by 
the addition of PD-1 blockade. Thus, we provide evidence that 
LAG-3 blockade alone is effective in boosting of T cell stimula-
tion by a strong antigenic stimulus, while the combination of 
LAG-3 and PD-1 blockade is more effective in the setting of weak 
T cell stimulation. This observation is in line with ex vivo T cell 
stimulation experiments with tumor-infiltrating lymphocytes of 
epithelial ovarian cancer patients, where dual blockade of LAG-3 
and PD-1 during priming of tumor antigen-specific T cells with 
tumor-derived APCs as weak stimulators increased T cell effector 
function to the levels observed with PB-derived APCs as stronger 
stimulators (32).
Our data set is focused on the priming phase of the immune 
response rather than the effector phase. The expression levels 
of checkpoint molecules on APCs clearly differ from those on 
tumor cells. Therefore, it is not surprising that the dominant 
effect of LAG-3 blockade and the relatively low effect of PD-1 
blockade that we see deviates from the results in animal studies 
(36) and the outstanding clinical effects observed with PD-1 
blockade as monotherapy or in combination with antineoplastic 
agents in clinical trials for various tumor entities. The effects 
observed in those studies rely on the effector phase of the 
immune response and are dependent on pre-existing effector 
T cells. Different immune checkpoints seem to be of importance 
in priming and effector phase, as directly shown for the epithelial 
ovarian cancer model, where LAG-3 blockade did not influ-
ence the effector function of already primed tumor-infiltrating 
T cells (32). Similarly, a 4-1BB agonist was more effective than 
an anti-LAG-3 blocking antibody as a combination partner for 
PD-1 blockade in a melanoma mouse model in the absence of 
any cancer vaccine (37). Recently, first data was published from 
an ongoing clinical trial (NCT01968109), in which anti-LAG-3 
in combination with anti-PD-1 showed activity in melanoma 
patients who were relapsed or refractory to anti-PD-1/-PD-L1 
therapy. The objective response rate (ORR) was 11.5% in 61 
efficacy-evaluable patients, and a correlation of higher ORR with 
a LAG-3 expression above 1% on tumor-associated immune cells 
was shown (38).
Checkpoint blockade has revolutionized cancer therapy in 
several entities, including melanoma, lung cancer, and urothelial 
carcinoma. To our current understanding, these results primarily 
rely on reversing adaptive immune escape mechanisms of the 
tumor cells in the context of an immune response. Our data, 
however, support the relevance of checkpoint inhibition within 
the induction of primary or secondary anti-tumor immune 
responses. Thus, checkpoint inhibitors might also be therapeu-
tically beneficial in tumor entities with a non-immunogenic 
microenvironment. Further studies will be needed to address 
the question of checkpoint inhibition within the priming versus 
effector phase of T cell responses. The sequencing and exact tim-
ing of LAG-3 and PD-1 blockade might be of particular relevance 
for the induction for optimal anti-tumor T cell responses.
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